These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36726477)

  • 21. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant.
    Khazaie H; Sadeghi M; Khazaie S; Hirshkowitz M; Sharafkhaneh A
    Front Psychiatry; 2022; 13():1070522. PubMed ID: 36578296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suvorexant in insomnia: efficacy, safety and place in therapy.
    Rhyne DN; Anderson SL
    Ther Adv Drug Saf; 2015 Oct; 6(5):189-95. PubMed ID: 26478806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of Safety and Efficacy of Sleep Medicines in Older Adults.
    Schroeck JL; Ford J; Conway EL; Kurtzhalts KE; Gee ME; Vollmer KA; Mergenhagen KA
    Clin Ther; 2016 Nov; 38(11):2340-2372. PubMed ID: 27751669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
    Winrow CJ; Renger JJ
    Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.
    Kuriyama A; Tabata H
    Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insomnia in Elderly Patients: Recommendations for Pharmacological Management.
    Abad VC; Guilleminault C
    Drugs Aging; 2018 Sep; 35(9):791-817. PubMed ID: 30058034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orexin Receptor Antagonists and Insomnia.
    Wu X; Xue T; Chen Z; Wang Z; Chen G
    Curr Psychiatry Rep; 2022 Oct; 24(10):509-521. PubMed ID: 35972717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients.
    Kawada K; Ohta T; Tanaka K; Miyamura M; Tanaka S
    J Stroke Cerebrovasc Dis; 2019 Jan; 28(1):142-148. PubMed ID: 30322756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suvorexant: The first orexin receptor antagonist to treat insomnia.
    Dubey AK; Handu SS; Mediratta PK
    J Pharmacol Pharmacother; 2015; 6(2):118-21. PubMed ID: 25969666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease.
    Svetnik V; Wang TC; Ceesay P; Snyder E; Ceren O; Bliwise D; Budd K; Hutzelmann J; Stevens J; Lines C; Michelson D; Herring WJ
    J Sleep Res; 2021 Dec; 30(6):e13328. PubMed ID: 34340251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial.
    Campbell EJ; Norman A; Bonomo Y; Lawrence AJ
    Brain Res; 2020 Feb; 1728():146597. PubMed ID: 31837287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The dual orexin receptor antagonist suvorexant in alcohol use disorder and comorbid insomnia: A case report.
    Campbell EJ; Bonomo Y; Collins L; Norman A; O'Neill H; Streitberg A; Galloway K; Kyoong A; Perkins A; Pastor A; Lawrence AJ
    Clin Case Rep; 2024 May; 12(5):e8740. PubMed ID: 38698873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suvorexant for the Treatment of Insomnia in Adolescents.
    Kawabe K; Horiuchi F; Ochi M; Nishimoto K; Ueno SI; Oka Y
    J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):792-795. PubMed ID: 28520464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
    Uemura N; McCrea J; Sun H; Donikyan M; Zammit G; Liu R; Louridas B; Marsilio S; Lines C; Troyer MD; Wagner J
    J Clin Pharmacol; 2015 Oct; 55(10):1093-100. PubMed ID: 25903940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans.
    Cui D; Cabalu T; Yee KL; Small J; Li X; Liu B; Maciolek C; Smith S; Liu W; McCrea JB; Prueksaritanont T
    Xenobiotica; 2016 Oct; 46(10):882-95. PubMed ID: 26864332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
    Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
    Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suvorexant: first global approval.
    Yang LP
    Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Morin CM; Lines C; Michelson D
    Sleep Med; 2019 Apr; 56():219-223. PubMed ID: 30522875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.